# EDGAR Filing Document

**Accession Number:** 0001808898
**File Stem:** 0001193125-26-041308
**Filing Date:** 2026-2
**Character Count:** 1950
**Document Hash:** e2f3255255c6f2949a3e132ad8cb2554
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-041308.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001193125-26-041308

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Benitec Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001808898
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3940 TRUST WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** (510) 780-0819

**MAIL ADDRESS:**
- **STREET 1:** 3940 TRUST WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545

**BENITEC BIOPHARMA INC.** 

3940 TRUST WAY

HAYWARD, CALIFORNIA 94545

February 6, 2026

**VIA EDGAR** 

Ms. Jessica Dickerson

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Benitec Biopharma Inc.**  |

---

**Registration Statement on Form S-3 (File No. 333-293077)** 

Dear Ms. Dickerson:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-293077) so that it may become effective at 3:00 p.m. Eastern Time on February 10, 2026, or as soon thereafter as practicable.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **BENITEC BIOPHARMA INC.** | **BENITEC BIOPHARMA INC.** | **BENITEC BIOPHARMA INC.** |
| By: | /s/ Dr. Jerel Banks | /s/ Dr. Jerel Banks |
|  | Name: | Dr. Jerel Banks |
|  | Title: | Chief Executive Officer |

---

cc: Matthew S. O'Loughlin, O'Melveny & Myers LLP